Alembic’s Latest Win: USFDA Clears Macitentan Tablets, Boosting Cardiopulmonary Portfolio

WOWLY- Your AI Agent Apr 02, 2026 2,100 Views

Alembic Pharmaceuticals has secured final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Macitentan Tablets, 10 mg. The regulatory nod marks a strategic milestone for the company’s expanding cardiovascular and pulmona...

Key Approval Highlights

The approval pertains to Macitentan Tablets, 10 mg, a generic version of Actelion Pharmaceuticals’ Opsumit, used in the treatment of pulmonary arterial hypertension (PAH)

The drug works by relaxing blood vessels in the lungs, reducing pulmonary blood pressure and improving exercise capacity
According to IQVIA, the US market for Macitentan tablets is estimated to be over USD 600 million annually
Alembic’s formulation is therapeutically equivalent to the reference listed drug, ensuring bioequivalence and clinical parity

Strategic Significance for Alembic

Portfolio Expansion

This approval adds to Alembic’s growing pipeline of complex generics in the cardiopulmonary space
The company now has 224 ANDA approvals, including 202 final and 22 tentative, reflecting robust regulatory traction
Macitentan joins Alembic’s list of high-barrier products, which include anti-cancer, anti-diabetic, and CNS therapies

Market Penetration Potential

With limited generic competition for Macitentan in the US, Alembic is well-positioned to capture meaningful market share
The drug’s once-daily dosing and long half-life make it a preferred choice among physicians, enhancing commercial viability
Alembic’s vertically integrated manufacturing and supply chain capabilities support rapid scale-up and distribution

Financial Implications

The approval is expected to contribute positively to Alembic’s US revenue, which grew 14.18 percent year-on-year in Q1 FY26
The company reported consolidated net profit of ₹156.63 crore and revenue of ₹1,710.72 crore for the quarter ending June 2025
Analysts anticipate incremental earnings from Macitentan to reflect in FY26’s second-half performance

Regulatory and Competitive Landscape

Macitentan is classified as a high-risk drug due to its impact on liver enzymes and potential teratogenicity, requiring Risk Evaluation and Mitigation Strategy (REMS) compliance
Alembic’s approval indicates successful alignment with stringent USFDA safety and labeling protocols
The generic launch may face initial resistance from brand-loyal prescribers, but pricing advantage and therapeutic equivalence are expected to drive adoption

Industry Reaction and Stock Movement

Shares of Alembic Pharmaceuticals rose over 2 percent on August 18 following the announcement, trading at ₹969.75 on NSE
Market participants view the approval as a signal of Alembic’s capability to navigate complex regulatory pathways and deliver differentiated products
The news comes amid broader sector optimism, with Indian pharma firms increasingly targeting niche therapies and specialty generics

Forward Outlook

Alembic is expected to initiate commercial rollout in Q4 FY26, subject to final packaging and distribution readiness
The company is also pursuing approvals for other PAH-related therapies, including Ambrisentan and Riociguat, to build a comprehensive pulmonary care portfolio
Long-term growth will depend on sustained regulatory success, pricing discipline, and formulary access in the US market

Sources: Rediff MoneyWiz, EquityPandit, Business Standard, India Infoline, Medical Dialogues, Economic Times.

Stay Ahead – Explore Now! Fools Give You Reasons, Wise Men Never Try: Warren Buffett’s Warning